Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies

Publisher： Karger

E-ISSN： 1423-0348|86|5|260-267

ISSN： 0033-3190

Source： Psychotherapy and Psychosomatics, Vol.86, Iss.5, 2017-09, pp. : 260-267

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate‐to‐severe psoriasis patients: 12‐week results from two phase III trials

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 32, Iss. 1, 2018-01 ,pp. : 68-72

John Wiley & Sons Inc

Access to resources Recommend Favorite

Infections from seven clinical trials of ixekizumab, an anti‐interleukin‐17A monoclonal antibody, in patients with moderate‐to‐severe psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 177, Iss. 6, 2017-12 ,pp. : 1537-1551

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of open‐label ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 6, 2015-06 ,pp. : 1148-1155

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 1, 2018-01 ,pp. : 132-139

John Wiley & Sons Inc

Access to resources Recommend Favorite

No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate‐to‐severe plaque psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 2, 2018-02 ,pp. : e105-e107

John Wiley & Sons Inc

Access to resources Recommend Favorite